An ACE2-based bimodular fusion protein enables reorientation of endogenous anti-Epstein-Barr virus antibodies towards SARS-CoV-2 Spike.
Arnaud CheneAlexandra DesramesAlice TomlinsonClaude RuffiéFrédéric TangyBenoît GamainPublished in: The Journal of infectious diseases (2023)
The use of soluble recombinant ACE2 (rACE2) as a decoy capable of blocking SARS-CoV-2 entry into cells has been envisaged as a therapeutic strategy to reduce viral loads in patients suffering from severe COVID-19. We engineered a novel form of rACE2, fused to the Epstein-Barr virus (EBV) antigen P18F3 (rACE2-P18F3), to reorient a pre-existing humoral response towards EBV against SARS-CoV-2 particles. Recombinant ACE2-P18F3 was able to bind to the SARS-CoV-2 spike protein, neutralized viral entry into cells and promoted the phagocytosis of spheres coated with different spike variants by monocytic cells. The results position rACE2-P18F3 as a promising therapeutic candidate to universally block coronaviruses cell entry and clear viral particles.
Keyphrases
- sars cov
- epstein barr virus
- diffuse large b cell lymphoma
- induced apoptosis
- respiratory syndrome coronavirus
- cell cycle arrest
- angiotensin ii
- end stage renal disease
- endoplasmic reticulum stress
- immune response
- angiotensin converting enzyme
- stem cells
- coronavirus disease
- chronic kidney disease
- gene expression
- early onset
- prognostic factors
- small molecule
- signaling pathway
- mesenchymal stem cells
- amino acid